AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Policy

AbbVie’s Mavyret Approved for Hep C in Pediatric and Adolescent Patients

The FDA gave the nod to AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older in 2017.

May 1, 2019

3 min read

Mark Terry

BioCapital

Top Life Science Companies Hiring Now in May

According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!

April 30, 2019

1 min read

Editorial Staff

BioMidwest

Reports: Odds of Getting Drugs to Market Range from 6% to 40%

Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.

April 30, 2019

3 min read

Mark Terry

Business

NHS England Teams with Gilead, Merck and AbbVie to Eliminate Hepatitis C

NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.

April 30, 2019

3 min read

Mark Terry

Policy

Under Fire, Biopharma Increases Lobbying Expenses to Influence Opinion and Legislation

One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.

April 24, 2019

4 min read

Mark Terry

FDA

FDA gives AbbVie’s Skyrizi a Thumbs-Up for Plaque Psoriasis

Plaque psoriasis is the most common type of psoriasis, caused by overproduction of skin cells. This causes inflamed, red lesions called plaques.

April 24, 2019

3 min read

Mark Terry

BioCapital

Patients Rank Pharma Companies in New Perspective Survey

The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.

April 19, 2019

2 min read

Alex Keown

BioMidwest

AbbVie Takes Top Spot in Best Place to Work Survey

The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.

April 9, 2019

2 min read

Alex Keown

Drug Development

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.

March 29, 2019

2 min read

Alex Keown

JOBS